Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02079168 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
A Phase 2 study, sponsored by RXi Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02079168: Completed Phase 2 study, sponsored by RXi Pharmaceuticals.
NCT02079168 is a Phase 2 study that has completed, run by RXi Pharmaceuticals. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02079168, a Phase 2 study, has completed, sponsored by RXi Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.
Primary Outcome
To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision
Interventions
- DRUG Placebo
- DRUG RXI-109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
What the finished NCT02079168 record still lists
NCT02079168 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02079168 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02079168 about?
NCT02079168 is a clinical study titled "A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults". To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.
What is the current status of trial NCT02079168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2014-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02079168?
The interventions under investigation include: Placebo (DRUG), RXI-109 (DRUG).
Who is sponsoring clinical trial NCT02079168?
This trial is sponsored by RXi Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02079168's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia